Peptide Comparison
Cagrilintide vs CagriSema
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
CagriSema has stronger documented evidence (Phase 3) than Cagrilintide (Phase 2/3) while both occupy the amylin class. When clinical-evidence tier is the deciding factor, CagriSema is the safer pick. Cagrilintide may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Shared safety considerations
Both compounds share these reported concerns: gi effects. Open each peptide page for the full risk paragraph and source citations.
Side-by-side
| Cagrilintide | CagriSema | |
|---|---|---|
| Class | Long-acting amylin analog | Amylin + GLP-1 combination |
| Drug class | Metabolic & Weight | Metabolic & Weight |
| Mechanism | Amylin receptor agonist; delays gastric emptying; enhances satiety | Dual amylin + GLP-1 receptor agonism |
| Route | SC injection | SC injection |
| Half-life | ~7 days | ~7 days |
| Dosage (research) | 0.3-4.5 mg SC weekly (often paired with semaglutide) | 2.4 mg / 2.4 mg SC weekly |
| Evidence tier | Phase 2/3 | Phase 3 |
| Research depth | 139 indexed | 113 indexed |
| Availability | Investigational | Investigational |
| Reported risks | Nausea; GI effects; long-term data pending | GI effects; Phase 3 REDEFINE mixed results |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Cagrilintide or CagriSema?
CagriSema has stronger documented evidence (Phase 3) than Cagrilintide (Phase 2/3) while both occupy the amylin class. When clinical-evidence tier is the deciding factor, CagriSema is the safer pick. Cagrilintide may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between Cagrilintide and CagriSema?
Cagrilintide is classed as Long-acting amylin analog; CagriSema is classed as Amylin + GLP-1 combination. Reported mechanism: Cagrilintide, Amylin receptor agonist; delays gastric emptying; enhances satiety; CagriSema, Dual amylin + GLP-1 receptor agonism. Reported half-life: Cagrilintide, ~7 days; CagriSema, ~7 days. Routes in published studies: Cagrilintide, SC injection; CagriSema, SC injection.
Which has stronger evidence, Cagrilintide or CagriSema?
CagriSema has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Cagrilintide is graded Phase 2/3, with 23 cited sources on its reference page and 139 indexed studies. CagriSema is graded Phase 3, with 25 cited sources on its reference page and 113 indexed studies.
Which is more accessible, Cagrilintide or CagriSema?
Neither Cagrilintide nor CagriSema is an FDA-approved drug. Catalog status: Cagrilintide, Investigational; CagriSema, Investigational.
Are Cagrilintide and CagriSema ever combined?
Cagrilintide and CagriSema appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…